Abstract
Treatment of patients with metastasized renal cell cancer with interferon-α2b (IFN-α2b) and interleukin-2 (IL-2) initially led to a drop in the total lymphocyte count and in all lymphocyte subpopulations with the exception of CD-19-positive cells. Upon termination of therapy, there was an excessive increase in all lymphocyte subpopulations. No correlation between the kinetics of the lymphocyte subpopulations and the clinical outcome of the patient was demonstrated. Significant stimulation of tumor necrosis factor-α (TNF-α) as a result of the treatment was not detected. This may indicate that stimulation of TNF-α by IL-2 is not an important effector mechanism.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ackermann R (1988) Immunologische Aspekte in der Behandlung des Nierenkarzinoms. In: Staehler G (ed) Das Nierenkarzinom. Springer, Berlin Heidelberg New York Tokyo, S 104–114.
Atzpodien J (1990) Home therapy with recombinant interleukin-2 and interferon-α 2b in advanced human malignancies. Lancet 335:1509–1512.
Blay JY et al (1990) Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor. Cancer Res 50:2371–2374.
Bono AV (1986) Steroid hormones and hormonal treatment in renal cell carcinoma. In: DeKernion JB, Pavone Macaluso M (eds) Tumors of the kidney, vol 13. Williams & Wilkins, Baltimore, pp 205–227.
Budd TJ et al (1989) Phase I clinical trial of interleukin-2 and α-interferon: toxicity and immunologic effects. Cancer Res 49:6432–6436.
DeKernion JB (1986) Treatment of advanced renal cell carcinoma. Traditional methods and innovative approaches. J Urol 130:2–7.
Dinarelle CA, Mier JW (1986) Interleukins. Ann Rev Med 37:173–178.
Domzig W et al (1983) Interleukin-2 dependence of human natural killer (NK) cell activity. J Immunol 130:1970–1973.
Fowler JE (1986) Failure of immunotherapy for metastatic renal cell carcinoma. J Urol 135:22–25.
Grimm EA et al (1982) Lymphokine-activated killer cell phenomenon. JExpMed 155:1823–1841.
Gumlo BT et al (1988) Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine activated killer cells. Cancer Res 48:5864–5867.
Hefeneider SH et al (1983) In vivo interleukin-2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident killer cells. J Immunol 130:222–227.
Kriegmair M, Hofstetter A (1989) Interferontherapie in der Urologie. Urologe [A] 28:116–121.
Krown SE (1987) Interferon treatment of renal cell carcinoma. Cancer 59 [Suppl]:647–651.
Marumo K et al (1989) Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma. Urology 33:219–225.
Mier JW et al (1988) Induction of circulating tumor necrosis factor (TNF-α) as the mechanism of the febrile response to IL-2 in our patients. J Clin Immunol 82:426–436.
Miltenburg AMM et al (1988) Lymphokine-activated killer cells lyse human renal cancer cell lines and cultured normal kidney cells. Immunology 63:729–731.
Neidhard JA et al (1984) Interferon-α therapy of renal cancer. Cancer Res 44:4140–4143.
Otto U et al (1988) Die Behandlung des metastasierten Nierenkarzinoms mit rekombinantem α-2-oder γ-Interferon. Onkologie 11:185–194.
Reem GH, Yeh NH (1984) Interleukin-2 regulates expression of its receptors and synthesis of γinterferon by human T lymphocytes. Science 225:429–430.
Rosenberg SA et al (1989) Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863–1874.
Urba WJ et al (1990) Immunomodulatory properties and toxicity of interleukin-2 in patients with cancer. Cancer Res 50:185–192.
West WH et al (1987) Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Manseck, A., Mansouri Taleghani, B., Wirth, M. (1991). Lymphocyte Subpopulations and Tumor Necrosis Factor During Interferon-α 2b and Interleukin-2 Therapy in Patients with Metastasized Renal Cell Cancer. In: Jocham, D., Thüroff, J.W., Rübben, H. (eds) Investigative Urology 4. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75972-7_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-75972-7_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-75974-1
Online ISBN: 978-3-642-75972-7
eBook Packages: Springer Book Archive